Plexium is a technology company.
Plexium is the premier, next-generation targeted protein degradation (TPD) company. We lead the way in the rational design and discovery of Monovalent Direct Degraders and Molecular Glues.
Plexium has raised $163.0M across 3 funding rounds.
Plexium has raised $163.0M in total across 3 funding rounds.
Plexium is a next-generation biotech company specializing in targeted protein degradation (TPD), focused on rationally designing and discovering monovalent protein degraders to treat diseases like cancer and neurodegeneration.[1][2] It builds a comprehensive TPD platform powered by proprietary ultra-high-throughput screening (uHTS) technology, including AI-integrated phenotypic assays and DNA-encoded libraries (DELs), to identify drug-like degraders beyond traditional PROTACs.[3][4] Plexium serves pharma and biotech partners such as Amgen and AbbVie, while advancing a wholly-owned pipeline targeting oncology indications like SMARCA4-deficient solid tumors and ER+/Her2- breast cancer.[5] The company solves the limitations of first-generation heterobifunctional degraders by enabling selective, cell-permeable monovalent options, demonstrating early promise in synthetic lethality and immune modulation for "undruggable" targets.[2][5]
Plexium emerged as a leader in TPD innovation, based in San Diego, California, with a focus on overcoming the constraints of early degrader technologies like PROTACs and cereblon imids.[1][2] While specific founding details and founder backgrounds are not detailed in available sources, the company has rapidly built a differentiated platform around ultra-high-throughput phenotypic screening of large chemical libraries in microfluidic devices, marking a pivotal shift toward monovalent degraders.[3][6] Early traction includes partnerships with major players like Amgen and AbbVie, validating its technology for collaborative discovery, alongside a robust internal pipeline of wholly-owned programs.[5]
Plexium stands out in the TPD field through several key strengths:
Plexium rides the explosive growth of targeted protein degradation, a paradigm shift in drug discovery that harnesses the ubiquitin-proteasome system (UPS) to tackle "undruggable" proteins previously inaccessible to small molecules.[1][3] Its timing aligns with surging biotech investment in TPD, fueled by clinical successes of PROTACs and the need for next-gen solutions amid rising cancer prevalence and immunotherapy demands.[2][5] Market forces like advances in AI-driven screening and DEL synthesis favor Plexium's platform, enabling faster, more efficient hit identification over traditional methods.[4] By partnering with Amgen and AbbVie while building internal assets, Plexium influences the ecosystem as a tech enabler, potentially expanding TPD's reach into neurodegeneration and combo therapies, reshaping precision oncology.[5]
Plexium is poised to advance its wholly-owned pipeline into clinical stages, with lead programs like SMARCA2 degraders and IKZF2 glues targeting high-unmet-need oncology niches through 2026 and beyond.[5] Trends in AI-accelerated discovery, molecular glue expansion, and TPD combos with checkpoint inhibitors will propel its momentum, especially as big pharma collaborations de-risk development.[2][4] Its influence may evolve from platform innovator to full-fledged therapeutic player, unlocking broader UPS modulation if preclinical synthetic lethality translates clinically—cementing its role as a TPD pioneer amid biotech's protein-targeting revolution.[1][3]
Plexium has raised $163.0M in total across 3 funding rounds.
Plexium's investors include Baidu Ventures, B Capital Group, Canaan Partners, Matt Ocko, DCVC (Data Collective), Dimension Capital, Footwork, Lux Capital, Mexican.vc, Pivotal bioVenture Partners, Spark Capital, Tencent Holdings.
Plexium has raised $163.0M across 3 funding rounds. Most recently, it raised $100.0M Series B in February 2022.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Feb 1, 2022 | $100.0M Series B | Baidu Ventures, B Capital Group, Canaan Partners, Matt Ocko, DCVC (Data Collective), Dimension Capital, Footwork, Lux Capital, Mexican.vc, Pivotal bioVenture Partners, Spark Capital, Tencent Holdings, The Column Group, Trajectory Ventures, Vickers Venture Partners, Alice Zhang, Farzad Nazem | |
| Jan 1, 2021 | $35.0M Series A | Canaan Partners, Dimension Capital, Footwork, Lux Capital, Pivotal bioVenture Partners, Spark Capital, Trajectory Ventures, Alice Zhang | |
| Oct 1, 2019 | $28.0M Series A | Baidu Ventures, B Capital Group, Matt Ocko, DCVC (Data Collective), Mexican.vc, Tencent Holdings, The Column Group, Vickers Venture Partners, Farzad Nazem |